A phase II study of upfront concurrent EGFR-TKI and thoracic radiotherapy for Stage IV EGFR-mutated NSCLC reported a grade 3+ radiation pneumonitis rate of 20% [64]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.